Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), announced today that Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's Cancer Center in Bethlehem, Pennsylvania, and professor of medicine at Temple University School of Medicine in Philadelphia, presented data on PV-10 as an investigational intralesional treatment of melanoma at the 2015 American Society of Clinical Oncology's Annual Meeting on May 31, 2015. A copy of the presentation can be found at: http://www.pvct.com/presentation/A_Changing_topography_IL_Rx_in_Melanoma.pdf
Dr. Agarwala chaired an education session titled "Locoregional Therapies in the Setting of Systemic Treatment Advances: What's Next?" The session was part of the conference's track: Melanoma/Skin Cancers; Developmental Therapeutics and Translational Research.
He identified the potential goals of intralesional treatment as local disease control (durable tumor shrinkage and symptom control and palliation), systemic effect (immune mediated), delay or prevention of systemic therapy and neoadjuvant potential. Next, the session covered the phase 3 trial results for TVEC, the phase 2 results for PV-10 as well as a review of the newly begun phase 3 trial for PV-10, a review of the phase 2 results for DNA IL-12, pIL-12 Monotherapy, and Coxsackievirus A21 (CVA21). Among the conclusions in the session, Dr. Agarwala stated that "several agents in development appear promising."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in